Category Archives: Op-Ed

The Rx Firm Tax Exodus: Is Something Wrong with the U.S. System?

As I read the latest reports of yet another big US Rx firm, this time AbbVie, trying to pull off a “tax inversion” takeover of the Irish-based Shire, I couldn’t help but wonder, what the heck is going on here? Right now, it feels like most major US corporations, especially pharmas, are literally running away […]
Also posted in Deals, Europe, Global, Guest Blog, Legal, Strategy | Tagged , , , , , , | Leave a comment

The Urge to Merge: Dealmaking Lessons from Pharma History

By Cliff Kalb. The major pressures hindering pharmaceutical industry success have not changed—payer constraints on drug costs, R&D productivity, an increasingly risk-averse regulatory climate, generic encroachment, and negative public perceptions linked to reputation. Looking at the latest rendition of the Pharma 50, prescription drug revenue rankings for the top 10 major global players in 2013 […]
Also posted in Deals, Global, Strategy | Tagged , , , | Leave a comment

The Long Tail: Behind This Year's Pharm Exec 50

Therapeutic specialization, competitive differentiation, and a finely-tailored value proposition are creating a new drug world of bespoke market niches—and infinite future possibilities for the best of this year’s Pharma 50. The vigorous return of M&A activity to biopharmaceuticals this year brings us back to the question that industry strategists have been posing for years: is […]
Also posted in Strategy | Tagged , , , , | Leave a comment

Does Pharma Have the Skills for Consumer Health?

By Michael Winter, Egon Zehnder. Consumer health, the business of selling health and wellness sustaining-brands in categories as diverse as pain relievers, brain-boosting yogurts, sports nutrition, baby food and bone supplement drinks, is poised to take off globally. With consumers becoming ever more health-aware and knowledgeable, companies from both the pharma and consumer segments are […]
Also posted in Guest Blog, healthcare, People | Tagged , , | Leave a comment

Sanofi Responds to UK’s Value-Based Assessment Plans

By Leela Barham. The UK’s National Institute for Health and Care Excellence (NICE) set out their proposals for value-based assessment (VBA) in March 2014.  VBA is what value-based pricing (VBP) has essentially morphed into. Much work is going on behind closed doors to inform responses as the consultation closing date of the 20th June 2014 […]
Also posted in Europe, Global, Guest Blog, healthcare, pricing, Regulatory | Tagged , , , , , | Leave a comment
  • Categories

  • Meta